当前位置： SCI文献检索 > CLINICAL NEUROPHARMACOLOGY期刊下所有文献 > Monamine oxidase inhibitors: current and emerging agents for Parkinson disease.

Monamine oxidase inhibitors: current and emerging agents for Parkinson disease.

Abstract：

:Monoamine oxidase type B (MAO-B) is the predominant isoform responsible for the metabolic breakdown of dopamine in the brain. Selective inhibition of brain MAO-B results in elevation of synaptosomal dopamine concentrations. Data have been reported regarding the selective MAO-B inhibitors, rasagiline and selegiline, for the symptomatic treatment of Parkinson disease (PD). Selegiline has demonstrated efficacy as monotherapy in patients with early PD (Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism study), but evidence of selegiline efficacy as adjunctive treatment in levodopa-treated PD patients with motor fluctuations is equivocal. A new formulation of selegiline (Zydis selegiline) has been evaluated in 2 small, placebo-controlled studies as adjunctive therapy to levodopa. The Zydis formulation allows pregastric absorption of selegiline, minimizing first-pass metabolism, and thereby increasing selegiline bioavailability and reducing the concentration of amphetamine metabolites. Rasagiline is a selective, second-generation, irreversible MAO-B inhibitor, with at least 5 times the potency of selegiline in vitro and in animal models. Rasagiline has demonstrated efficacy in 1 large, randomized, double-blind, placebo-controlled trial (TVP-1012 in Early Monotherapy for Parkinson's Disease Outpatients) as initial monotherapy in patients with early PD, and in 2 large, controlled trials (Parkinson's Rasagiline: Efficacy and Safety in the Treatment of "Off," Lasting Effect in Adjunct Therapy With Rasagiline Given Once Daily) as adjunctive treatment in levodopa-treated PD patients with motor fluctuations. Unlike selegiline, rasagiline is an aminoindan derivative with no amphetamine metabolites. A randomized clinical trial is underway to confirm preclinical and preliminary clinical data suggesting rasagiline has disease-modifying effects.

journal_name

Clin Neuropharmacol

journal_title

Clinical neuropharmacology

authors

Fernandez HH,Chen JJ

doi

10.1097/01.wnf.0000240956.49315.be

subject

Has Abstract

pub_date

2007-05-01 00:00:00

pages

150-68

issue

eissn

0362-5664

issn

1537-162X

pii

00002826-200705000-00004

journal_volume

pub_type

杂志文章,评审

在线工具

Monamine oxidase inhibitors: current and emerging agents for Parkinson disease.